Hepatitis B is the most common serious liver infection in the world, with about 350 million people who are infected with the hepatitis B virus (HBV) and about 1 million deaths annually. Hepatitis B is characterized by an acute and a chronic phase, if the subject fails to produce adequate immune response. About 5-10% of adults infected with HBV go on to develop chronic infection and become chronic carriers (CHB); moreover, the liver damage, if not stopped, continues until cirrhosis or hepatocellular carcinoma. In the natural history of HBV infection, the most important event is HBeAg seroconversion, characterized by loss of HBeAg (a specific antigen of the virus) and development of Anti-HBe antibodies (HBeAg-positive patients). If the seroconversion has occurred early (when liver damage is not yet significant) and is maintained, long-term prognosis is excellent. The disease can follow a more aggressive course if active viral replication persists despite anti-HBe positivity. This state, characterized by continuing viral replication, has been termed as HBeAg-negative CHB, and is the most prevalent form in Italy. At the moment, there are 4 approved antiviral drug classes, with different antiviral efficacy, for the treatment of chronic hepatitis B: interferons, nucleoside analogues, nucleotide analogues, and cyclopents. The primary target of the treatment is a prolonged suppression of viral replication, in order to avoid long term complications and increase survival.
IndIcatIons and dosIng
Entecavir (ETV) is a new active substance, a guanosine analogue with selective activity against HBV, indicated for the treatment of chronic hepatitis B in adults with compensated liver disease, evidence of active viral replication and signs of liver damage. The drug is available in two pharmaceutical forms: film-coated tablets, which contain 0.5 or 1 mg of ETV anhydrous, and oral solution (0.05 mg/ml of active substance). Entecavir is taken once daily, with a dose of 0.5 mg for patients never treated with a nucleoside analogue and with a dose of 1 mg in patients refractory to lamivudine (LVD). This drug is currently included by AIFA (Agenzia Italiana del Farmaco) in a drug efficacy and safety monitoring program.
PharmacokInetIcs
Pharmacokinetics of ETV is characterized by a moderate inter-individual variability. Coadministration of food reduces Cmax by about 50% and AUC by 20%, while Tmax is increased; PK/PD modeling showed that in treatment of naïve subjects ETV could be taken with or without food, but in LVD-refractory patients this drug must be taken at least 2 hours before or after meals. Cmax and AUC increased in patients with renal impairment and in elderly subjects; for this population base dose adjustment is required.
PharmacodynamIcs
Entecavir is a cyclopentyl guanine analogue and inhibits selectively HBV polymerase (reverse transcriptase) by competing with the natural substrate deoxyguanosine triphosphate.
effIcacy and safety
Three phase III trials have been conducted to test ETV efficacy and safety: two of them (AI463-022 and AI463-027) in nucleoside-naïve subjects, and one (AI463-026) in lamivudine-refractory subjects. The primary objective of these studies was to evaluate the efficacy of ETV versus lamivudine treatment in chronic hepatitis B patients with compensated liver disease. The primary efficacy measure for nucleoside-naïve subjects trials is the proportion of subjects who achieved histological improvement, defined as ≥2 points decrease in the Knodell necroinflammatory score with no worsening of fibrosis compared to baseline. In the AI463-026 study (LVD-refractory subjects) there are two co-primary endpoints, the histologic improvement
entecavir (Baraclude) in patients with chronic hepatitis B virus (hPV) infection

Edited by AdRes Health Economics & Outcomes Research
and the composite endpoint, definite as the proportion of subjects with undetectable HBV DNA (<0.7 mEq/ml) and normalization of serum ALT (<1.25 x ULN). Subjects are differentiated in HBeAg-positive (HBeAg+) and HBeAg-negative (HBeAg-): HBeAg is a portion of the core antigen of the virus generally released during the infectiveness phase, and its persistence in the serum is associated with active chronic hepatitis. Duration of all main studies was 52 weeks for subjects with complete response (HBV DNA <0.7 mEq/ml and HBeAg-) or no response (HBV DNA >0.7 mEq/ml), extended to 92 weeks for partial responders (HBV DNA <0.7 mEq/ml and HBeAg+). The statistical histological, biological and virological superiority of ETV compared to LVD was demonstrated at 48 and 24 weeks, and also in patients resistant to LVD. The safety profile of the drug is comparable to the one of LVD, although the question about ETV cancerogenity is still open; animals studies suggest a potential cancerogenic effect for the drug, and clinical follow-up data reported an incidence of 3.5/1,000 cases of hepatocarcinomas in ETV-treated patients. Currently there are six approved drugs for the hepatitis B therapy: interferon alpha-2b, pegylated interferon alpha-2a, and four oral monotherapeutic agents (adefovir dipivoxil, entecavir, lamivudine and telbivudine). Injectable interferons and oral drugs represent two different pharmacological approaches, the first based on host immunity stimulation, and the other on a direct antiviral action. Furthermore, polymerase inhibitors need to be indefinitely administered since they are unable to induce a sustained response, even after years of continuous administration. Nevertheless, costs of treatment with oral drugs represent a drastic reduction compared to subcutaneous therapy, and these treatments are also associated with a good response rate and an excellent safety profile, making the overall treatment cost effective.
The main limitation of these drugs is the emerging of resistance during the treatment: in particular patients treated with lamivudine, which is effective and not expensive, reported high resistance rates, ranging from 14%-32% after 1 year of therapy to 58% with 2-3 years. ETV, ADF, LVD Subjects: HBV pts with cirrhosis The study evaluated the cost-effectiveness of six strategies:
(1) No HBV treatment ("do nothing") (2) LVD monotherapy (3) ADF monotherapy (4) LVD with crossover to ADF on resistance ("ADF salvage") (5) ETV monotherapy (6) LVD with crossover to ETV on resistance ("ETV salvage")
(1) least effective yet least expensive (3) vs (1) incremental cost of $ 19,731 (5) vs (3) more effective yet more expensive, incremental cost 25,626 $/QALY (2), (4) and (6) not costeffective (4) vs (6) more effective and less expensive Both ETV and ADF are cost-effective in pts with HBV cirrhosis; choosing between ADF and ETV is highly dependent on available budgets. In pts who developed LVD resistance, "ADF salvage" appears more effective and less expensive than "ETV salvage" In Table III we reviewed the main economic evaluations we found in PubMED for ETV. Generally this drug appears to be cost-effective in chronic hepatitis B therapy, particularly if compared to LVD. LVD, the first oral nucleoside analog approved for the treatment of CHB, presents a lower acquisition cost ($ 4,671 less per patient per year respect to ETV), but patients treated with this drug reported high resistence rates (14-32% vs 0% of ETV); both adefovir and ETV present lower viral resistance rates, but are more expensive. The cost-effectiveness of ETV compared with adefovir for nucleos(t)ide treatment-naïve patients is in need of investigation.
In Table IV we calculated the monthly pharmaceutical cost in Italy of available hepatitis B treatment: this is not to be intended as a cost-minimization analysis, but as a simple overlook of currently available treatments. Considered dosages are those derived from reference trials or from the SPCs of the products. For interferon alpha-2b, we considered a dosing of 9-10 MUI/3 times a week for HBeAg+ patients and of 5-6 MUI/3 times a week for HBeAg-, as seen in a national treatment protocol. Prices of the drugs are derived from Informatore Farmaceutico 2008: we always considered ex-factory price. Globally, the monthly cost of telbivudine is nearly the same of entecavir (€ 379), and similar to the one of adefovir; the cost of peginterferon is almost twice, and the less costly drug results lamivudine, with a monthly cost of about € 54. 
